A Phase 1/2 interventional study of FT-2102 and Azacitidine in Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) and Cohort 3a and 3b: Chondrosarcoma, sponsored by Forma Therapeutics, Inc.. Completed at 26 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Forma Therapeutics, Inc. (part of Novo Nordisk A/S) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.
Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 174th largest by enrollment of the 1,155 interventional ones that give a count, is one of 72 that started in 2018, is one of 190 in phase 1/2, and was the 881st registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:
Macarena De La Fuente, MD · Sites in United States
Ages 18+
Alpheus Medical, Inc. · Sites in United States
Ages 18–80
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Inova Health Care Services · Sites in United States
Ages 18–98
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,302 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 671 · Phase 2 592 · Phase 3 55 · Phase 4 4
First in 1979; this study’s year is marked. 72 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 33 across the 1,155 interventional studies, 60 across the 79 observational. Of the 882 that completed or were terminated, 344 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
321 of 1,302 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forma Therapeutics, Inc., one of the names counted as Novo Nordisk A/S. Under that name alone:
Forma Therapeutics, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Novo Nordisk A/S has 1 study filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
105 of the studies in Glioblastoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT03743662Memorial Sloan Kettering Cancer CenterNivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | 2026-11 |
| NCT04574856University of Michigan Rogel Cancer CenterMultiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2026-11-19 |
| NCT02704858Neonc Technologies, Inc.Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | 2026-11-30 |
| NCT05781321Mayo ClinicShort Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | 2026-11-30 |
Add all 105 to your calendar (.ics) → With an account.
Among the 1,302 studies in Glioblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas.
The study is divided into two parts: single agent FT-2102 followed by combination therapy.
Part 1: A single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dose confirmation followed by a Phase 2 investigation of clinical activity in up to 4 cohorts. During the dose confirmation, additional doses or altered dose schedules may be explored.
Part 2: An open-label study of FT-2102 in combination with other anti-cancer agents. Patients will be enrolled across 4 different disease cohorts, examining the effect of FT-2102 + azacitidine (glioma and chondrosarcoma), FT-2102 + nivolumab (hepatobiliary tumors), and FT-2102 + gemcitabine/cisplatin (intrahepatic cholangiocarcinoma). There will be a safety lead-in followed by a Phase 2 evaluation in up to four cohorts of patients.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: FT-2102
Drug: FT-2102
Drug: FT-2102 · Drug: Azacitidine
Drug: FT-2102 · Biological: Nivolumab
Drug: FT-2102 · Drug: Gemcitabine and Cisplatin
FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
Azacitidine will be administered per the site's standard of care.
Also known as: Vidaza
Nivolumab will be administered per the site's standard of care.
Also known as: Opdivo
Drug pages: Gemcitabine · Cisplatin
Gemcitabine and cisplatin will be administered per the site's standard of care.
Also known as: Gemzar and Platinol
Number of Participants With a Dose Limiting Toxicity (DLT)
DLTs are AEs unrelated to the underlying disease and considered related to FT-2102. For non-hematologic AEs: Grade 3 or higher per CTCAE v 4.03 criteria except Grade 3 nausea, vomiting, diarrhea, or rash: lasting \<72 hours (with optimal medical management) or clinically relevant Grade 3 or higher non-hematologic laboratory finding. For hematologic AEs: Grade 3 or higher thrombocytopenia or febrile neutropenia or Grade 4 or higher neutropenia lasting for \>7 days.
Time frame: Day 1-28
Overall Response Rate (ORR)
ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) as per RANO (2010) criteria for patients with high grade glioma (Cohorts 1a and 1b). For patients with low grade glioma, ORR is defined as CR+PR+minor response (MR) as per LGG RANO criteria (2011). For Cohorts 2-5, ORR is defined as CR+PR as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
Time frame: While on treatment
Area Under the Plasma Concentration Versus Time Curve (AUC)
Area under the plasma concentration versus time curve (AUC) summarized for Cycle 1 and Cycle 2
Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Peak Plasma Concentration (Cmax)
Peak Plasma Concentration (Cmax) was summarized for Cycle 1 and Cycle 2.
Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Time of Peak Plasma Concentration (Tmax)
Time of peak plasma concentration (Tmax) was summarized for Cycle 1 and Cycle 2.
Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Time for Half of the Drug to be Absent in Blood Stream Following Dose (T 1/2)
Time for half of the drug to be absent in blood stream following dose (T 1/2)
Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Apparent Clearance (CL/F)
Rate at which drug is removed from the blood stream (CL/F).
Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Rate of Drug Distribution Within the Blood Stream (Vd/F)
Rate of drug distribution within the blood stream (Vd/F)
Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Olutasidenib Concentration Within Cerebro-spinal Fluid (CSF)
Olutasidenib concentration within CSF (Glioma Cohorts 1-A and 1-B only). Due to sparse data, analysis was not conducted by timepoint.
Time frame: CSF sample for drug concentration was collected at Day 1 of Cycles 1 and 3 (each cycle is 28 days) and through study completion, up to 24 weeks, on average.
Progression-Free Survival (PFS)
Progression-Free Survival from time of entry on study. Progression-free survival (PFS) is defined as the time from the first dose to disease progression as determined by applicable disease criteria or death due to any cause, whichever was sooner. Disease progression as measured by the appropriate response criteria, unless deemed by the Investigator to be receiving clinical benefit
Time frame: From time of entry on study through progression, up to 24 weeks, on average
Time to Progression (TTP)
Time to progression is defined as the time (in weeks) from start of treatment until disease specified progression.
Time frame: From first dose of study drug through time of disease progression
Duration of Response (DOR)
Duration of response (DOR), defined as the time from the first response to documented disease progression as determined by applicable disease criteria. First response is defined as first observation of overall response of CR+PR+MR (glioma) or CR+PR (Cohort 2-5). Disease progression as measured by the appropriate response criteria, unless deemed by the Investigator to be receiving clinical benefit
Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 44 weeks
Overall Survival (OS)
Overall survival (OS), defined as the time in weeks from the first dose to death due to any cause or date last known alive at end of follow-up
Time frame: From date of first dose until the date of death from any cause, assessed up to 101 weeks
Time to Response (TTR)
Time to response (TTR) in weeks. TTR is defined as the time from first dose to first response. First response is defined as first observation of overall response of CR+PR+MR (glioma) or CR+PR (Cohort 2-5).
Time frame: Response may be observed from time of first dose through time of treatment discontinuation, up to 2 years.
| Milestone | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 2B | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 5A |
|---|---|---|---|---|---|---|---|---|---|
| Started | 26 | 6 | 8 | 0 | 23 | 0 | 24 | 0 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 26 | 6 | 8 | 0 | 23 | 0 | 24 | 0 | 6 |
DLTs are AEs unrelated to the underlying disease and considered related to FT-2102. For non-hematologic AEs: Grade 3 or higher per CTCAE v 4.03 criteria except Grade 3 nausea, vomiting, diarrhea, or rash: lasting \<72 hours (with optimal medical management) or clinically relevant Grade 3 or higher non-hematologic laboratory finding. For hematologic AEs: Grade 3 or higher thrombocytopenia or febrile neutropenia or Grade 4 or higher neutropenia lasting for \>7 days.
| Participants | Cohort 1A | Cohort 1B | Cohort 3A | Cohort 5A |
|---|---|---|---|---|
| Number of Participants With a Dose Limiting Toxicity (DLT) | 0 | 2 | 0 | 1 |
ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) as per RANO (2010) criteria for patients with high grade glioma (Cohorts 1a and 1b). For patients with low grade glioma, ORR is defined as CR+PR+minor response (MR) as per LGG RANO criteria (2011). For Cohorts 2-5, ORR is defined as CR+PR as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
| Participants | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 2 | 0 | 1 | 0 | 0 | 0 |
Area under the plasma concentration versus time curve (AUC) summarized for Cycle 1 and Cycle 2
| h*ng/mL | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Cycle 1 | 6840 ± 3062.9 | 6190 ± 2113.0 | 13140 ± 6018.9 | 12000 ± 2907.1 | 10780 ± 6379.1 | 11030 ± 6781.6 |
| Cycle 2 | 20390 ± 5975.5 | 21210 ± 5775.0 | 27580 ± 4531.3 | 28170 ± 9052.5 | 24400 ± 8663.1 | 39540 ± 12573 |
Peak Plasma Concentration (Cmax) was summarized for Cycle 1 and Cycle 2.
| ng / mL | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Cycle 1 | 388.1 ± 154.92 | 369.5 ± 127.84 | 879.4 ± 432.37 | 863.4 ± 313.71 | 744.1 ± 526.73 | 815.4 ± 432.32 |
| Cycle 2 | 2965 ± 917.89 | 2870 ± 540.28 | 4045 ± 527.02 | 4104 ± 1326.0 | 3650 ± 985.06 | 5663 ± 1897.8 |
Time of peak plasma concentration (Tmax) was summarized for Cycle 1 and Cycle 2.
| hours | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Cycle 1 | 4.18 (1.95 to 20.25) | 3.95 (1.92 to 27.23) | 15.27 (2.03 to 24.33) | 16.37 (1.02 to 23.92) | 7.50 (1.00 to 24.00) | 4.17 (1.00 to 23.05) |
| Cycle 2 | 1.97 (0.00 to 7.57) | 4.00 (3.97 to 4.05) | 1.05 (1.00 to 7.85) | 1.98 (0.95 to 4.00) | 1.04 (0.00 to 4.22) | 1.52 (0.00 to 7.58) |
Time for half of the drug to be absent in blood stream following dose (T 1/2)
| ng / mL | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Time for Half of the Drug to be Absent in Blood Stream Following Dose (T 1/2) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Rate at which drug is removed from the blood stream (CL/F).
| units | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Apparent Clearance (CL/F) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Rate of drug distribution within the blood stream (Vd/F)
| units | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Rate of Drug Distribution Within the Blood Stream (Vd/F) | NA | NA | NA | NA | NA | NA |
Olutasidenib concentration within CSF (Glioma Cohorts 1-A and 1-B only). Due to sparse data, analysis was not conducted by timepoint.
| ng/mL | Cohort 1A | Cohort 1B |
|---|---|---|
| Olutasidenib Concentration Within Cerebro-spinal Fluid (CSF) | 27.15 ± 6.57 | — |
Progression-Free Survival from time of entry on study. Progression-free survival (PFS) is defined as the time from the first dose to disease progression as determined by applicable disease criteria or death due to any cause, whichever was sooner. Disease progression as measured by the appropriate response criteria, unless deemed by the Investigator to be receiving clinical benefit
| weeks | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) | 8.21 (7.14 to 37.50) | 8.29 (8.14 to 9.43) | NA (7.00 to NA) | 8.57 (7.43 to 22.14) | 8.29 (7.00 to 17.71) | 8.07 (7.57 to 31.00) |
Time to progression is defined as the time (in weeks) from start of treatment until disease specified progression.
| weeks | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Time to Progression (TTP) | 8.21 (7.14 to 37.50) | 8.29 (8.14 to 9.43) | NA (7.0 to NA) | 15.00 (7.43 to 24.00) | 13.86 (7.29 to 24.14) | 8.14 (8.00 to 31.00) |
Duration of response (DOR), defined as the time from the first response to documented disease progression as determined by applicable disease criteria. First response is defined as first observation of overall response of CR+PR+MR (glioma) or CR+PR (Cohort 2-5). Disease progression as measured by the appropriate response criteria, unless deemed by the Investigator to be receiving clinical benefit
| weeks | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Duration of Response (DOR) | 43.71 (43.71 to 43.71) | — | NA (NA to NA) | — | — | — |
Overall survival (OS), defined as the time in weeks from the first dose to death due to any cause or date last known alive at end of follow-up
| weeks | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Overall Survival (OS) | 75.00 (45.86 to NA) | NA (NA to NA) | NA (32.00 to NA) | NA (23.14 to NA) | 36.43 (10.29 to NA) | NA (33.71 to NA) |
Time to response (TTR) in weeks. TTR is defined as the time from first dose to first response. First response is defined as first observation of overall response of CR+PR+MR (glioma) or CR+PR (Cohort 2-5).
| weeks | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Time to Response (TTR) | 38.07 (8.29 to 67.86) | — | 31.43 (31.43 to 31.43) | — | — | — |
Collected over From first dose of study drug up to 28 days after last dose (Up to approximately 2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1A | 2/26 (7.7%) | 11/26 (42.3%) | 26/26 (100%) |
| Cohort 1B | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Cohort 2A | 0/8 (0%) | 5/8 (62.5%) | 8/8 (100%) |
| Cohort 3A | 2/23 (8.7%) | 12/23 (52.2%) | 21/23 (91.3%) |
| Cohort 4A | 4/24 (16.7%) | 9/24 (37.5%) | 23/24 (95.8%) |
| Cohort 5A | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Event | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Disease ProgressionGeneral disorders | 6/26 | 1/6 | 1/8 | 5/23 | 6/24 | 1/6 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/26 | 1/6 | 0/8 | 0/23 | 0/24 | 0/6 |
| Hepatic enzyme increasedInvestigations | 0/26 | 1/6 | 0/8 | 1/23 | 0/24 | 0/6 |
| Decreased appetiteMetabolism and nutrition disorders | 0/26 | 0/6 | 0/8 | 0/23 | 0/24 | 1/6 |
| Abdominal infectionInfections and infestations | 0/26 | 0/6 | 1/8 | 0/23 | 0/24 | 0/6 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/26 | 0/6 | 1/8 | 0/23 | 0/24 | 0/6 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/26 | 0/6 | 1/8 | 0/23 | 1/24 | 0/6 |
| HeadacheNervous system disorders | 0/26 | 0/6 | 1/8 | 0/23 | 0/24 | 0/6 |
| SeizureNervous system disorders | 2/26 | 0/6 | 0/8 | 1/23 | 0/24 | 0/6 |
| Anal incontinenceGastrointestinal disorders | 0/26 | 0/6 | 0/8 | 1/23 | 0/24 | 0/6 |
| Event | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A |
|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 8/26 | 5/6 | 3/8 | 7/23 | 9/24 | 4/6 |
| NauseaGastrointestinal disorders | 14/26 | 4/6 | 6/8 | 15/23 | 9/24 | 4/6 |
| Aspartate aminotransferase increasedInvestigations | 5/26 | 4/6 | 2/8 | 7/23 | 11/24 | 4/6 |
| Blood alkaline phosphatase increasedInvestigations | 2/26 | 2/6 | 4/8 | 6/23 | 8/24 | 4/6 |
| ConstipationGastrointestinal disorders | 7/26 | 2/6 | 4/8 | 7/23 | 6/24 | 3/6 |
| DiarrhoeaGastrointestinal disorders | 8/26 | 1/6 | 1/8 | 2/23 | 5/24 | 3/6 |
| VomitingGastrointestinal disorders | 5/26 | 1/6 | 2/8 | 3/23 | 3/24 | 3/6 |
| FatigueGeneral disorders | 13/26 | 2/6 | 3/8 | 7/23 | 8/24 | 1/6 |
| Neutrophil count decreasedInvestigations | 1/26 | 3/6 | 1/8 | 1/23 | 2/24 | 0/6 |
| Decreased appetiteMetabolism and nutrition disorders | 3/26 | 0/6 | 4/8 | 10/23 | 5/24 | 3/6 |
Safety Analysis Set - Patients who have received at least one dose of study medication.
| Age, Continuous(years) | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A | Total |
|---|---|---|---|---|---|---|---|
| Mean | 44.8 ± 9.13 | 42.0 ± 7.21 | 59.9 ± 10.47 | 55.1 ± 10.68 | 57.1 ± 12.56 | 61.3 ± 18.3 | 52.7 ± 12.6 |
| Sex: Female, Male(Participants) | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A | Total |
|---|---|---|---|---|---|---|---|
| Female | 9 | 2 | 6 | 6 | 17 | 4 | 44 |
| Male | 17 | 4 | 2 | 17 | 7 | 2 | 49 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 0 | 2 | 2 | 0 | 7 |
| Not Hispanic or Latino | 22 | 5 | 5 | 15 | 16 | 4 | 67 |
| Unknown or Not Reported | 2 | 0 | 3 | 6 | 6 | 2 | 19 |
| Race (NIH/OMB)(Participants) | Cohort 1A | Cohort 1B | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 3 | 0 | 1 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 25 | 6 | 3 | 17 | 17 | 3 | 71 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 2 | 6 | 5 | 2 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2018 to primary completion in May 2021, 30 months.
Results were first posted in Jan 2023, 1 year 8 months after primary completion. A results delay was requested in May 2022.
Of 53 industry-sponsored phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 75. This study's 30 months is below that.
Counting every sponsor, half of 138 studies reached it within 68 months; a quarter within 47 and three quarters within 102.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olutasidenib